间充质干细胞与低流量体外生命支持在烟雾吸入伤和烧伤所致ARDS及多器官衰竭中的辅助治疗效果
该研究在烟雾吸入伤合并40% TBSA烧伤的猪模型中,比较了同种异体/自体间充质干细胞(MSC)与两种低流量体外生命支持(ECLS)系统对组织学终末器官损伤的影响。结果显示自体MSC组72小时存活率最高(90%),MSC组弥漫性肺泡损伤评分显著低于未治疗组和ECLS组。结论认为自体MSC在减轻ARDS和多器官衰竭严重程度方面最为有效。
要点
- 自体MSC组72小时存活率90%,高于未治疗组40%和两种ECLS组(33%、63%)。
- MSC组弥漫性肺泡损伤评分显著低于未治疗组和ECLS组。
- PaO2/FiO2比值<300与弥漫性肺泡损伤评分独立相关(OR 1.074)。
核心结论
- 自体MSC在减轻该模型ARDS和多器官衰竭严重程度方面最为有效,其次为同种异体MSC和NovaLung。
研究设计与样本
- 麻醉雌性猪接受烟雾吸入伤和40% TBSA烧伤后重症监护72小时,设CTR(无损伤,n=4)、ICTR(损伤未治疗,n=10)、Allo(同种异体MSC,n=10)、Auto(自体MSC,n=10)、Hemo(Hemolung低流量ECLS,n=9)、Nova(NovaLung低流量ECLS,n=8)六组。
主要发现
- 72小时存活率:CTR 100%、ICTR 40%、Allo 50%、Auto 90%、Hemo 33%、Nova 63%。
- ARDS发生率:CTR 0/10、ICTR 10/10、Hemo 8/9、Nova 5/8、Allo 9/10、Auto 6/10。
- 所有损伤组均存在弥漫性肺泡损伤(DAD)。
- MSC组DAD评分显著低于ICTR组(Allo 26.6±3.4、Auto 18.9±1.5 vs. ICTR 46.8±2.1,p<0.001)。
- MSC组DAD评分亦低于ECLS组(Allo vs. Nova p<0.05,Allo vs. Hemo p<0.001,Auto vs. Nova p<0.001,Auto vs. Hemo p<0.001)。
临床怎么用
- 在烟雾吸入伤合并烧伤所致ARDS模型中,自体MSC可能作为辅助治疗减轻组织学终末器官损伤。
- 低流量ECLS在本模型中未显著改善DAD评分,且Hemo组肾损伤评分高于对照组。
- PaO2/FiO2比值<300与DAD评分相关,可作为监测损伤严重程度的参考指标。
局限性
- 研究为动物模型(猪),样本量有限(各组n=4–10),结果外推至临床需谨慎。
- 未评估MSC与ECLS联合治疗的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated effects of mesenchymal stem cells (MSC) or low-flow extracorporeal life support (ECLS) as adjunctive treatments for acute respiratory distress syndrome (ARDS) due to inhalation injury and burns. We hypothesized that these interventions decrease histological end-organ damage. METHODS: Anesthetized female swine underwent smoke inhalation injury and 40% TBSA burns, then critical care for 72h. The following groups were studied: CTR (no injury, n = 4), ICTR (injured untreated, n = 10), Allo (injured treated with allogenic MSC, n = 10), Auto (injured treated with autologous MSC, n = 10), Hemo (injured and treated with the Hemolung low flow ECLS system, n = 9), and Nova (injured and treated with the NovaLung low flow ECLS system, n = 8). Histology scores from lung, kidneys, liver, and jejunum were calculated. Data are presented as means±SEM. RESULTS: Survival at 72h was 100% in CTR; 40% in ICTR; 50% in Allo; 90% in Auto; 33% in Hemo; 63% in Nova. ARDS developed in 0/10 CTR; 10/10 ICTR; 8/9 Hemo; 5/8 Nova; 9/10 Allo; 6/10 Auto. Diffuse alveolar damage (DAD) was present in all injured groups. MSC groups had significantly lower DAD scores than ICTR animals (Allo 26.6 ± 3.4 and Auto 18.9 ± 1.5 vs. ICTR 46.8 ± 2.1, p < 0.001). MSC groups also had lower DAD scores than ECLS animals (Allo vs. Nova, p < 0.05, Allo vs. Hemo p < 0.001, Auto vs. Nova p < 0.001, Auto vs. Hemo, p < 0.001). Kidney injury ICTR (p < 0.05) and Hemo (p < 0.01) were higher than in CTR. By logistic regression, a PaO2-to-FiO2 ratio (PFR) < 300 was a function of the DAD score: logit (PFR < 300) = 0.84 + 0.072*DAD Score, odds ratio 1.074 (1.007, 1.147, p < 0.05) with a ROC AUC of 0.76, p < 0.001. CONCLUSION: Treatment with Auto MSC followed by Allo and then Nova were most effective in mitigating ARDS and MOF severity in this model. Further studies will elucidate the role of combination therapies of MSC and ECLS as comprehensive treatments for ARDS and MOF.
引用
- Choi JH, Necsoiu C, Wendorff D, et al. Effects of adjunct treatments on end-organ damage and histological injury severity in acute respiratory distress syndrome and multiorgan failure caused by smoke inhalation injury and burns. Burns. 2019. PMID: 31378621. doi:10.1016/j.burns.2019.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。